Download PDF
Semin Respir Crit Care Med 2005; 26(5): 458-481
DOI: 10.1055/s-2005-922030
Copyright © 2005 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Drug-Induced Respiratory Disease in Patients with Hematological Diseases

Philippe Camus1 , Ulrich Costabel2
  • 1Department of Pulmonary Medicine, Hopital Le Bocage, Dijon, France
  • 2Department of Pneumology/Allergy, Ruhrlandklinik, Essen, Germany
Further Information

Publication History

Publication Date:
02 November 2005 (online)

    Permissions and Reprints

ABSTRACT

Patients with hematological malignancies or recipients of hematopoietic stem cell transplants may develop myriad pulmonary manifestations, as a complication of either the disease or the diverse agents used to treat the disease. Clinical, radiographic, and physiological features of drug-induced and radiation-induced pulmonary injury are often difficult to distinguish from other causes of pulmonary infiltrates (e.g., infections, pulmonary edema, alveolar hemorrhage, etc.). Fiberoptic bronchoscopy with bronchoalveolar lavage (BAL) is essential to exclude infectious etiologies. In some cases, surgical lung biopsies are required to establish a specific etiological diagnosis. This review discusses the myriad causes of lung injury/toxicity that may afflict patients with hematological malignancies or transplant recipients, and presents diagnostic and therapeutic approaches.

KEYWORDS

Drug-induced pneumonitis - radiation pneumonitis - chemotherapy-induced lung

REFERENCES

  • 1 Limper A H. Chemotherapy-induced lung disease.  Clin Chest Med. 2004;  25 53-64
    CrossrefPubMedGoogle Scholar
  • 2 Afessa B. Pretransplant pulmonary evaluation of the blood and marrow transplant recipient.  Chest. 2005;  128 8-10
    CrossrefPubMedGoogle Scholar
  • 3 Stiff P J, Unger J M, Forman S J et al.. The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease: a Southwest Oncology Group phase II trial.  Biol Blood Marrow Transplant. 2003;  9 529-539
    CrossrefPubMedGoogle Scholar
  • 4 Fryer C J, Hutchinson R J, Krailo M et al.. Efficacy and toxicity of 12 courses of ABVD chemotherapy followed by low-dose regional radiation in advanced Hodgkin's disease in children: a report from the Children's Cancer Study Group.  J Clin Oncol. 1990;  8 1971-1980
    PubMedGoogle Scholar
  • 5 Rossi H A, Becker P S, Emmons R V et al.. High-dose cyclophosphamide, BCNU, and VP-16 (CBV) conditioning before allogeneic stem cell transplantation for patients with non-Hodgkin's lymphoma.  Bone Marrow Transplant. 2003;  31 441-446
    CrossrefPubMedGoogle Scholar
  • 6 Stuart M J, Chao N S, Horning S J et al.. Efficacy and toxicity of a CCNU-containing high-dose chemotherapy regimen followed by autologous hematopoietic cell transplantation in relapsed or refractory Hodgkin's disease.  Biol Blood Marrow Transplant. 2001;  7 552-560
    PubMedGoogle Scholar
  • 7 Engelfriet C P, Reesink H W, Brand A et al.. Transfusion-related acute lung injury (TRALI).  Vox Sang. 2001;  81 269-283
    CrossrefPubMedGoogle Scholar
  • 8 Abratt R P, Onc F R, Morgan G W, Silvestri G, Willcox P. Pulmonary complications of radiation therapy.  Clin Chest Med. 2004;  25 167-177
    CrossrefPubMedGoogle Scholar
  • 9 http://www.pneumotox.com Pneumotox® Web site: 1997. Producers: P Foucher-Ph. Camus: Last update: July, 2005
    Google Scholar
  • 10 Bruno B, Souillet G, Bertrand Y, Werck-Gallois M C, So Satta A, Bellon G. Effects of allogeneic bone marrow transplantation on pulmonary function in 80 children in a single paediatric centre.  Bone Marrow Transplant. 2004;  34 143-147
    CrossrefPubMedGoogle Scholar
  • 11 White D A. Drug-induced pulmonary infection.  Clin Chest Med. 2004;  25 179-188
    CrossrefPubMedGoogle Scholar
  • 12 Khurshid I, Anderson L C. Non-infectious pulmonary complications after bone marrow transplantation: thoracic complications related to bone marrow transplantation.  Postgrad Med J. 2002;  78 257-262
    CrossrefPubMedGoogle Scholar
  • 13 Franquet T, Muller N L, Lee K S, Gimenez A, Flint J D. High-resolution CT and pathologic findings of noninfectious pulmonary complications after hematopoietic stem cell transplantation.  AJR Am J Roentgenol. 2005;  184 629-637
    PubMedGoogle Scholar
  • 14 Plataki M, Bouros D. Iatrogenic and rare pleural effusion. In: Bouros D Pleural Disorders. New York; Dekker 2004: 897-913
    Google Scholar
  • 15 Zisman D A, McCune W J, Tino G, Lynch J PI. Drug-induced pneumonitis: the role of methotrexate.  Sarcoidosis Vasc Diffuse Lung Dis. 2001;  18 243-252
    PubMedGoogle Scholar
  • 16 Sleijfer S. Bleomycin pneumonitis.  Chest. 2001;  120 617-624
    CrossrefPubMedGoogle Scholar
  • 17 O'Driscoll B R, Hasleton P S, Taylor P M, Poulter L W, Gattamaneni H R, Woodcock A A. Active lung fibrosis up to 17 years after chemotherapy with carmustine (BCNU) in childhood.  N Engl J Med. 1990;  323 378-382
    PubMedGoogle Scholar
  • 18 Erasmus J J, McAdams H P, Rossi S E. Drug-induced lung injury.  Semin Roentgenol. 2002;  37 72-81
    PubMedGoogle Scholar
  • 19 Erasmus J J, McAdams H P, Rossi S E. High-resolution CT of drug-induced lung disease.  Radiol Clin North Am. 2002;  40 61-72
    PubMedGoogle Scholar
  • 20 Cleverley J R, Screaton N J, Hiorns M P, Flint J D, Müller N L. Drug-induced lung disease: high-resolution CT and histological findings.  Clin Radiol. 2002;  57 292-299
    CrossrefPubMedGoogle Scholar
  • 21 Mulabecirovic A, Gaulhofer P, Auner H W et al.. Pulmonary infiltrates in patients with haematologic malignancies: transbronchial lung biopsy increases the diagnostic yield with respect to neoplastic infiltrates and toxic pneumonitis.  Ann Hematol. 2004;  83 420-422
    CrossrefPubMedGoogle Scholar
  • 22 Flieder D B, Travis W D. Pathologic characteristics of drug-induced lung disease.  Clin Chest Med. 2004;  25 37-46
    CrossrefPubMedGoogle Scholar
  • 23 Bolanos-Meade J, Ioffe O, Hey J C, Vogelsang G B, Akpek G. Lymphocytic pneumonitis as the manifestation of acute graft-versus-host disease of the lung.  Am J Hematol. 2005;  79 132-135
    CrossrefPubMedGoogle Scholar
  • 24 Kremer J M, Alarcon G S, Weinblatt M E et al.. Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis.  Arthritis Rheum. 1997;  40 1829-1837
    CrossrefPubMedGoogle Scholar
  • 25 Imokawa S, Colby T V, Leslie K O, Helmers R A. Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients.  Eur Respir J. 2000;  15 373-381
    CrossrefPubMedGoogle Scholar
  • 26 Rossi S E, Erasmus J J, McAdams P, Sporn T A, Goodman P C. Pulmonary drug toxicity: radiologic and pathologic manifestations.  Radiographics. 2000;  5 1245-1259
    PubMedGoogle Scholar
  • 27 Fuhrman C, Parrot A, Wislez M et al.. Spectrum of CD4 to CD8 T-cell ratios in lymphocytic alveolitis associated with methotrexate-induced pneumonitis.  Am J Respir Crit Care Med. 2001;  164 1186-1191
    PubMedGoogle Scholar
  • 28 Marzouk K, Saleh S, Kannass M, Sharma O P. Interferon-induced granulomatous lung disease.  Curr Opin Pulm Med. 2004;  10 435-440
    CrossrefPubMedGoogle Scholar
  • 29 Berkani K, Bayle J Y, Perol M, Bejui-Thivolet F, Perrot D, Guérin J C. “Spontaneous” resolution of two severe methotrexate-induced pneumonias.  Rev Pneumol Clin. 2003;  59 301-305
    PubMedGoogle Scholar
  • 30 Fehr T, Jacky E, Bachli E B. Successful reintroduction of methotrexate after acute, pneumonitis in a patient with acute lymphoblastic leukemia.  Ann Hematol. 2003;  82 193-196
    PubMedGoogle Scholar
  • 31 Oddo M, Liaudet L, Lepori M, Broccard A F, Schaller M D. Relapsing acute respiratory failure induced by minocycline.  Chest. 2003;  123 2146-2148
    CrossrefPubMedGoogle Scholar
  • 32 Baptista J P, Casanova P C, Sousa J P et al.. Acute eosinophilic pneumonia associated with acute respiratory distress syndrome: case report.  Rev Port Pneumol. 2004;  10 355-364
    PubMedGoogle Scholar
  • 33 Gaensler E A, Carrington C B. Peripheral opacities in chronic eosinophilic pneumonia: the photographic negative of pulmonary edema.  AJR Am J Roentgenol. 1977;  128 1-13
    PubMedGoogle Scholar
  • 34 Egerer G, Witzens M, Spaeth A et al.. Successful treatment of bronchiolitis obliterans organizing pneumonia with low-dose methotrexate in a patient with Hodgkin's disease.  Oncology. 2001;  61 23-27
    CrossrefPubMedGoogle Scholar
  • 35 Kalambokis G, Stefanou D, Arkoumani E, Kitsanou M, Bourantas K, Tsianos E V. Fulminant bronchiolitis obliterans organizing pneumonia following 2 d of treatment with hydroxyurea, interferon-alpha and oral cytarabine ocfosfate for chronic myelogenous leukemia.  Eur J Haematol. 2004;  73 67-70
    CrossrefPubMedGoogle Scholar
  • 36 Ferriby D, Stojkovic T. Bronchiolitis obliterans with organizing pneumonia during interferon β-1a treatment.  Lancet. 2001;  357 751
    CrossrefPubMedGoogle Scholar
  • 37 Santrach P J, Askin F B, Wells R J, Azizkhan R G, Merten D F. Nodular form of bleomycin-related pulmonary injury in patients with osteogenic sarcoma.  Cancer. 1989;  64 806-811
    PubMedGoogle Scholar
  • 38 Gehl H B, Hauptmann S, Sohn M, Bohndorf K. Late pulmonary changes following bleomycin administration in computed tomography: nodular fibrosis mimicking a seminoma metastasis.  Radiologe. 1992;  32 80-82
    PubMedGoogle Scholar
  • 39 Ben Arush M W, Roguin A, Zamir E et al.. Bleomycin and cyclophosphamide toxicity simulating metastatic nodules to the lungs in childhood cancer.  Pediatr Hematol Oncol. 1997;  14 381-386
    PubMedGoogle Scholar
  • 40 Kreisman H, Wolkove N. Pulmonary toxicity of antineoplastic therapy.  Semin Oncol. 1992;  19 508-520
    PubMedGoogle Scholar
  • 41 Friedberg J W, Neuberg D, Kim H et al.. Gemcitabine added to doxorubicin, bleomycin, and vinblastine for the treatment of de novo Hodgkin disease: unacceptable acute pulmonary toxicity.  Cancer. 2003;  98 978-982
    CrossrefPubMedGoogle Scholar
  • 42 Bredenfeld H, Franklin J, Nogova L et al.. Severe pulmonary toxicity in patients with advanced-stage Hodgkin's disease treated with a modified bleomycin, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone, and gemcitabine (BEACOPP) regimen is probably related to the combination of gemcitabine and bleomycin: a report of the German Hodgkin's lymphoma Study Group.  J Clin Oncol. 2004;  22 2424-2429
    CrossrefPubMedGoogle Scholar
  • 43 Rubio C, Hill M E, Milan S, O'Brien M ER, Cunningham D. Idiopathic pneumonia syndrome after high dose chemotherapy for relapsed Hodgkin's disease.  Br J Cancer. 1997;  75 1044-1048
    PubMedGoogle Scholar
  • 44 Quigley M, Brada M, Heron C, Horwich A. Severe lung toxicity with a weekly low dose chemotherapy regimen in patients with non-Hodgkin's lymphoma.  Hematol Oncol. 1988;  6 319-324
    PubMedGoogle Scholar
  • 45 Todd N W, Peters W P, Ost A H, Roggli V L, Piantadosi A C. Pulmonary drug toxicity in patients with primary breast cancer treated with high-dose combination chemotherapy and autologous bone marrow transplantation.  Am Rev Respir Dis. 1993;  147 1264-1270
    PubMedGoogle Scholar
  • 46 Colby T V. Surgical pathology of non-neoplastic lung disease.  Mod Pathol. 2000;  13 343-358
    CrossrefPubMedGoogle Scholar
  • 47 Huang M S, Colby T V, Goellner J R, Martin W J. Utility of bronchoalveolar lavage in the diagnosis of drug induced pulmonary toxicity.  Acta Cytol. 1989;  33 533-538
    PubMedGoogle Scholar
  • 48 Maehara K, Shiraki M, Hara I, Koike S, Matsumiya T. Possible association of drug therapy with pulmonary alveolar proteinosis (PAP) in patients with malignant haematological disorders.  Jpn J Pharmacol. 1999;  79 285P
    PubMedGoogle Scholar
  • 49 Du E Z, Yung G L, Le D T, Masliah E, Yi E S, Friedman P J. Severe alveolar proteinosis following chemotherapy for acute myeloid leukemia in a lung allograft recipient.  J Thorac Imaging. 2001;  16 307-309
    CrossrefPubMedGoogle Scholar
  • 50 Kantrow S P, Hackman R C, Boeckh M, Myerson D, Crawford S W. Idiopathic pneumonia syndrome: changing spectrum of lung injury after marrow transplantation.  Transplantation. 1997;  63 1079-1086
    PubMedGoogle Scholar
  • 51 Cao T M, Negrin R S, Stockerl-Goldstein K E et al.. Pulmonary toxicity syndrome in breast cancer patients undergoing BCNU-containing high-dose chemotherapy and autologous hematopoietic cell transplantation.  Biol Blood Marrow Transplant. 2000;  6 387-394
    CrossrefPubMedGoogle Scholar
  • 52 Shankar G, Cohen D A. Idiopathic pneumonia syndrome after bone marrow transplantation: the role of pre-transplant radiation conditioning and local cytokine dysregulation in promoting lung inflammation and fibrosis.  Int J Exp Pathol. 2001;  82 101-113
    CrossrefPubMedGoogle Scholar
  • 53 Wong R, Rondon G, Saliba R M et al.. Idiopathic pneumonia syndrome after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for high-risk breast cancer.  Bone Marrow Transplant. 2003;  31 1157-1163
    CrossrefPubMedGoogle Scholar
  • 54 Shapiro C L, Yeap D Y, Godleski J et al.. Drug-related pulmonary toxicity in non-Hodgkin's lymphoma: comparative results with three different treatment regimens.  Cancer. 1991;  68 699-705
    PubMedGoogle Scholar
  • 55 Moormeier J A, Williams S F, Kaminer L S, Garner M, Bitran J D. High-dose tri-alkylator chemotherapy with autologous stem cell rescue in patients with refractory malignancies.  J Natl Cancer Inst. 1990;  82 29-34
    PubMedGoogle Scholar
  • 56 Alessandrino E P, Bernasconi P, Colombo A et al.. Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies.  Bone Marrow Transplant. 2000;  25 309-313
    CrossrefPubMedGoogle Scholar
  • 57 Brice P, Tredaniel J, Monsuez J J et al.. Cardiopulmonary toxicity after three courses of ABVD and mediastinal irradiation in favorable Hodgkin's disease.  Ann Oncol. 1991;  2(Suppl 2) 73-76
    PubMedGoogle Scholar
  • 58 Kalaycioglu M, Kavuru M, Tuason L, Bolwell B. Empiric prednisone therapy for pulmonary toxic reaction after high-dose chemotherapy containing carmustine.  Chest. 1995;  107 482-487
    PubMedGoogle Scholar
  • 59 Bhalla K S, Wilczynski S W, Abushamaa A M et al.. Pulmonary toxicity of induction chemotherapy prior to standard or high-dose chemotherapy with autologous hematopoietic support.  Am J Respir Crit Care Med. 2000;  161 17-25
    PubMedGoogle Scholar
  • 60 Maher J, Daly P A. Severe bleomycin lung toxicity: reversal with high dose corticosteroids.  Thorax. 1993;  48 92-94
    PubMedGoogle Scholar
  • 61 Segura A, Yuste A, Cercos A et al.. Pulmonary fibrosis induced by cyclophosphamide.  Ann Pharmacother. 2001;  35 894-897
    CrossrefPubMedGoogle Scholar
  • 62 Lindell R M, Hartman T E. Chest imaging in iatrogenic respiratory disease.  Clin Chest Med. 2004;  25 15-24
    CrossrefPubMedGoogle Scholar
  • 63 Dai M S, Lee S C, Ho C L, Chen Y C, Kao W Y, Chao T Y. Impact of open lung biopsy for undiagnosed pulmonary infiltrates in patients with hematological malignancies.  Am J Hematol. 2001;  68 87-90
    CrossrefPubMedGoogle Scholar
  • 64 Chap L, Shpiner R, Levine M, Norton L, Lill M, Glaspy J. Pulmonary toxicity of high-dose chemotherapy for breast cancer: a non-invasive approach to diagnosis and treatment.  Bone Marrow Transplant. 1997;  20 1063-1067
    CrossrefPubMedGoogle Scholar
  • 65 White D A, Wong P W, Downey R. The utility of open lung biopsy in patients with hematologic malignancies.  Am J Respir Crit Care Med. 2000;  161 723-729
    PubMedGoogle Scholar
  • 66 Richter J E, Hastedt R, Dalton J F, Marshall D, Raymond L W. Pulmonary toxicity of bischloronitrosourea: report of a case with transient response to corticosteroid therapy.  Cancer. 1979;  43 1607-1612
    PubMedGoogle Scholar
  • 67 White D A, Orenstein M, Godwin T A, Stover D E. Chemotherapy-associated pulmonary toxic reactions during treatment for breast cancer.  Arch Intern Med. 1984;  144 953-956
    CrossrefPubMedGoogle Scholar
  • 68 Zappasodi P, Vitulo P, Volpini E, Castagnola C, Nascimbene C, Corso A. Successful therapy with high-dose steroids and cyclosporine for the treatment of carmustine-mediated lung injury.  Ann Hematol. 2002;  81 347-349
    CrossrefPubMedGoogle Scholar
  • 69 Bell M R, Meredith D J, Gill P G. Role of carbon monoxide diffusing capacity in the early detection of major bleomycin-induced pulmonary toxicity.  Aust NZJ Med. 1985;  15 235-240
    PubMedGoogle Scholar
  • 70 Lind P A, Marks L B, Jamieson T A et al.. Predictors for pneumonitis during locoregional radiotherapy in high-risk patients with breast carcinoma treated with high-dose chemotherapy and stem-cell rescue.  Cancer. 2002;  94 2821-2829
    CrossrefPubMedGoogle Scholar
  • 71 Wolkowicz J, Sturgeon J, Rawji M, Chan C K. Bleomycin-induced pulmonary function abnormalities.  Chest. 1992;  101 97-101
    PubMedGoogle Scholar
  • 72 Tucker A S, Newman A J, Alvorado C. Pulmonary, pleural and thoracic changes complicating chemotherapy.  Radiology. 1977;  125 805-809
    PubMedGoogle Scholar
  • 73 Malik S W, Myers J L, DeRemee R A, Specks U. Lung toxicity associated with cyclophosphamide use: two distinct patterns.  Am J Respir Crit Care Med. 1996;  154 1851-1856
    CrossrefPubMedGoogle Scholar
  • 74 [No authors listed.] . The Hamman-Rich syndrome following treatment of lymphoma with chlorambucil.  J La State Med Soc. 1975;  127 311-315
    PubMedGoogle Scholar
  • 75 Bedrossian C WM, Miller W C, Luna M A. Methotrexate-induced diffuse interstitial pulmonary fibrosis.  South Med J. 1979;  72 313-318
    PubMedGoogle Scholar
  • 76 Attar E C, Ervin T, Janicek M, Deykin A, Godleski J. Acute interstitial pneumonitis related to gemcitabine.  J Clin Oncol. 2000;  18 697-698
    PubMedGoogle Scholar
  • 77 Hirschi S, Lange F, Battesti J P, Lebargy F. Pulmonary sarcoid-like granulomatosis associated with Hodgkin's disease and complicated by bleomycin-induced pulmonary nodules.  Ann Med Interne (Paris). 1998;  149 164-166
    PubMedGoogle Scholar
  • 78 Kornacker M, Kraemer A, Leo E, Ho A D. Occurrence of sarcoidosis subsequent to chemotherapy for non-Hodgkin's lymphoma: report of two cases.  Ann Hematol. 2002;  81 103-105
    CrossrefPubMedGoogle Scholar
  • 79 Vandenplas O, Hanston P, Dive A, Mahieu P. Fulminant pulmonary edema following intravenous administration of radiographic media.  Acta Clin Belg. 1990;  45 334-339
    PubMedGoogle Scholar
  • 80 Vaylet F, Plotton C, Algayres J P, Verkindre C, L'Her P. Oedème aigu du poumon après vinorelbine.  Presse Med. 1996;  25 1259-1260
    PubMedGoogle Scholar
  • 81 Reed C R, Glauser F L. Drug-induced non cardiogenic pulmonary edema.  Chest. 1991;  100 1120-1124
    PubMedGoogle Scholar
  • 82 Briasoulis E, Pavlidis N. Noncardiogenic pulmonary edema: an unusual and serious complication of anticancer therapy.  Oncologist. 2001;  6 153-161
    CrossrefPubMedGoogle Scholar
  • 83 Briasoulis E, Froudarakis M, Milionis H, Peponis I, Constantopoulos S, Pavlidis N. Chemotherapy-induced noncardiogenic pulmonary edema related to gemcitabine plus docetaxel combination with granulocyte colony-stimulating factor support.  Respiration. 2000;  67 680-683
    CrossrefPubMedGoogle Scholar
  • 84 Schwarz M I, Fontenot A P. Drug-induced diffuse alveolar hemorrhage syndromes and vasculitis.  Clin Chest Med. 2004;  25 133-140
    CrossrefPubMedGoogle Scholar
  • 85 Corso S, Vukelja S J, Wiener D, Baker W J. Diffuse alveolar hemorrhage following autologous bone marrow infusion.  Bone Marrow Transplant. 1993;  12 301-303
    PubMedGoogle Scholar
  • 86 Srivastava A, Gottlieb D, Bradstock K F. Diffuse alveolar haemorrhage associated with microangiopathy after allogeneic bone marrow transplantation.  Bone Marrow Transplant. 1995;  15 863-867
    PubMedGoogle Scholar
  • 87 Glasier C M, Siegel M J. Multiple pulmonary nodules: unusual manifestation of bleomycin toxicity.  AJR Am J Roentgenol. 1981;  137 155-156
    PubMedGoogle Scholar
  • 88 Franchi F, Seminara P, Gualdi G F. Lung pseudometastases due to vinblastine toxicity.  Klin Wochenschr. 1984;  62 1047-1048
    CrossrefPubMedGoogle Scholar
  • 89 Scharstein R, Johnson J F, Cook B A, Stephenson S R. Bleomycin nodules mimicking metastatic osteogenic sarcoma.  Am J Pediatr Hematol Oncol. 1987;  9 219-221
    PubMedGoogle Scholar
  • 90 Garg S, Garg M S, Basmaji N. Multiple pulmonary nodules: an unusual presentation of fludarabine pulmonary toxicity: case report and review of literature.  Am J Hematol. 2002;  70 241-245
    CrossrefPubMedGoogle Scholar
  • 91 Gulbahce H E, Manivel J C, Jessurun J. Pulmonary cytolytic thrombi: a previously unrecognized complication of bone marrow transplantation.  Am J Surg Pathol. 2000;  24 1147-1152
    CrossrefPubMedGoogle Scholar
  • 92 Gulbahce H E, Pambuccian S E, Jessurun J et al.. Pulmonary nodular lesions in bone marrow transplant recipients: impact of histologic diagnosis on patient management and prognosis.  Am J Clin Pathol. 2004;  121 205-210
    CrossrefPubMedGoogle Scholar
  • 93 White D A, Schwartzberg L S, Kris M G, Bosl G J. Acute chest pain syndrome during bleomycin infusions.  Cancer. 1987;  59 1582-1585
    PubMedGoogle Scholar
  • 94 Hudson M M, Weinstein H J, Donaldson S S et al.. Acute hypersensitivity reactions to etoposide in a VEPA regimen for Hodgkin's disease.  J Clin Oncol. 1993;  11 1080-1084
    PubMedGoogle Scholar
  • 95 Yano S, Shimada K. Vasospastic angina after chemotherapy by with carboplatin and etoposide in a patient with lung cancer.  Jpn Circ J. 1996;  60 185-188
    CrossrefPubMedGoogle Scholar
  • 96 Urban C, Nirenberg A, Caparros B, Anac S, Cacavio A, Rosen G. Chemical pleuritis as the cause of acute chest pain following high-dose methotrexate treatment.  Cancer. 1983;  51 34-37
    PubMedGoogle Scholar
  • 97 Brandt R R, Dunn W F, Ory S J. Dextran 70 embolization: another cause of pulmonary hemorrhage, coagulopathy, and rhabdomyolysis.  Chest. 1993;  104 631-633
    PubMedGoogle Scholar
  • 98 Rubin R L. Drug-induced lupus.  Toxicology. 2005;  209 135-147
    CrossrefPubMedGoogle Scholar
  • 99 Rivera M P, Kris M G, Gralla R J, White D A. Syndrome of acute dyspnea related to combined mitomycin plus vinca alkaloid chemotherapy.  Am J Clin Oncol. 1995;  18 245-250
    PubMedGoogle Scholar
  • 100 Dillman R O. Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy.  Cancer Metastasis Rev. 1999;  18 465-471
    CrossrefPubMedGoogle Scholar
  • 101 Benekli M, Anderson B, Wentling D, Bernstein S, Czuczman M, McCarthy P. Severe respiratory depression after dimethylsulphoxide-containing autologous stem cell infusion in a patient with AL amyloidosis.  Bone Marrow Transplant. 2000;  25 1299-1301
    CrossrefPubMedGoogle Scholar
  • 102 Shanholtz C. Acute life-threatening toxicity of cancer treatment.  Crit Care Clin. 2001;  17 483-502
    CrossrefPubMedGoogle Scholar
  • 103 Ferrucci P F, Martinoni A, Cocorocchio E. Evaluation of acute toxicities associated with autologous peripheral blood progenitor cell reinfusion in patients undergoing high-dose chemotherapy.  Bone Marrow Tranplant. 2002;  25 173-177
    PubMedGoogle Scholar
  • 104 Mills B A, Roberts R W. Cyclophosphamide-induced cardiomyopathy.  Cancer. 1979;  43 2223-2226
    PubMedGoogle Scholar
  • 105 Manthorpe R, Svensson O. Cardiomyopathy following intravenous cyclophosphamide therapy in a patient with Wegener's granulomatosis.  Clin Exp Rheumatol. 1996;  14 702-703
    PubMedGoogle Scholar
  • 106 Hayek E R, Speakman E, Rehmus E. Acute doxorubicin cardiotoxicity.  N Engl J Med. 2005;  352 2456-2457
    CrossrefPubMedGoogle Scholar
  • 107 Levine S J, Walsh T J, Martinez A, Eichacker P Q, Lopez-Berestein G, Natanson C. Cardiopulmonary toxicity after liposomal amphotericin B infusion.  Ann Intern Med. 1991;  114 664-666
    PubMedGoogle Scholar
  • 108 Vincent L, Lamrini R, Pommier P, Martel I, Helfre S, Carrie C. Arrêt cardiaque et vinorelbine? A propos d'un cas et revue de la littérature.  Rev Pneumol Clin. 1997;  53 360-361
    PubMedGoogle Scholar
  • 109 Prosnitz R G, Chen Y H, Marks L B. Cardiac toxicity following thoracic radiation.  Semin Oncol. 2005;  32 S71-S80
    PubMedGoogle Scholar
  • 110 Heidenreich P A, Hancock S L, Lee B K, Mariscal C S, Schnittger I. Asymptomatic cardiac disease following mediastinal irradiation.  J Am Coll Cardiol. 2003;  42 743-749
    CrossrefPubMedGoogle Scholar
  • 111 Camus P. Drug-induced pleural disease. In: Bouros D Pleural Disorders. York; Dekker 2004: 317-352
    Google Scholar
  • 112 Hamada K, Nagai S, Kitaichi M et al.. Cyclophosphamide-induced late-onset lung disease.  Intern Med. 2003;  42 82-87
    PubMedGoogle Scholar
  • 113 Jensen B V, Carlsen N LT, Groth S, Nissen N I. Late effects on pulmonary function of mantle-field irradiation, chemotherapy or combined modality therapy for Hodgkin's disease.  Eur J Haematol. 1990;  44 165-171
    PubMedGoogle Scholar
  • 114 Fanfulla F, Locatelli F, Zoia M C et al.. Pulmonary complications and respiratory function changes after bone marrow transplantation in children.  Eur Respir J. 1997;  10 2301-2306
    CrossrefPubMedGoogle Scholar
  • 115 Hoppe R T. Hodgkin's disease: complications of therapy and excess mortality.  Ann Oncol. 1997;  8 115-118
    CrossrefPubMedGoogle Scholar
  • 116 van Leeuwen F E, Klokman W J, Stovall M et al.. Roles of radiotherapy and smoking in lung cancer following Hodgkin's disease.  J Natl Cancer Inst. 1995;  87 1530-1537
    PubMedGoogle Scholar
  • 117 Travis L B, Gospodarowicz M, Curtis R E et al.. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease.  J Natl Cancer Inst. 2002;  94 182-192
    PubMedGoogle Scholar
  • 118 Gilbert E S, Stovall M, Gospodarowicz M et al.. Lung cancer after treatment for Hodgkin's disease: focus on radiation effects.  Radiat Res. 2003;  159 161-173
    PubMedGoogle Scholar
  • 119 Swerdlow A J, Schoemaker M J, Allerton R et al.. Lung cancer after Hodgkin's disease: a nested case-control study of the relation to treatment.  J Clin Oncol. 2001;  19 1610-1618
    PubMedGoogle Scholar
  • 120 Zablotska L B, Angevine A H, Neugut A I. Therapy-induced thoracic malignancies.  Clin Chest Med. 2004;  25 217-224
    CrossrefPubMedGoogle Scholar
  • 121 Tolar J, Coad J E, Ramsay N KC, Peters C, Davies S M. Lymphoproliferative disorder presenting as pulmonary nodules after bone marrow transplantation.  Bone Marrow Transplant. 2001;  28 808-810
    CrossrefPubMedGoogle Scholar
  • 122 Wright D G, Robichaud K J, Pizzo P A, Deiseroth A B. Lethal pulmonary reactions associated with the combined use of amphotericin B and leukocyte transfusions.  N Engl J Med. 1981;  304 1185-1189
    CrossrefPubMedGoogle Scholar
  • 123 Arning M, Heer-Sonderhoff A H, Wehmeir A, Schneider W. Pulmonary toxicity during infusion of liposomal amphotericin B in two patients with acute leukemia.  Eur J Clin Microbiol Infect Dis. 1995;  14 41-43
    CrossrefPubMedGoogle Scholar
  • 124 Garnacho-Montero J, Ortiz-Leyba C, Garcia-Garmenda J L, Jiminez-Jiminez F J. Life-threatening adverse event after amphotericin B lipid complex treatment in a patient treated previously with amphotericin B deoxycholate.  Clin Infect Dis. 1998;  26 1016
    PubMedGoogle Scholar
  • 125 Spitzer T R, Creger R J, Fox R M, Lazarus H M. Rapid infusion amphotericin B: effective and well-tolerated therapy for neutropenic fever.  Pharmatherapeutica. 1989;  5 305-311
    PubMedGoogle Scholar
  • 126 Lowery M M, Greenberger P A. Amphotericin-induced stridor: a review of stridor, amphotericin preparations, and their immunoregulatory effects.  Ann Allergy Asthma Immunol. 2003;  91 460-466
    PubMedGoogle Scholar
  • 127 Collazos J, Martinez E, Mayo J, Ibarra S. Pulmonary reactions during treatment with amphotericin B: review of published cases and guidelines for management.  Clin Infect Dis. 2001;  33 E75-E82
    CrossrefPubMedGoogle Scholar
  • 128 Maillard N, Foucher P, Caillot D, Durand C, Sgro C, Camus P. Transient pulmonary infiltrates during treatment with anti-thymocyte globulin.  Respiration. 1999;  66 279-282
    CrossrefPubMedGoogle Scholar
  • 129 Castaigne S, Chomienne C, Daniel M T et al.. All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia, I: Clinical results.  Blood. 1990;  76 1704-1709
    PubMedGoogle Scholar
  • 130 Frankel S R, Eardley A, Lauwers G, Weiss M, Warrell Jr R P. The “retinoic acid syndrome” in acute promyelocytic leukemia.  Ann Intern Med. 1992;  117 292-296
    PubMedGoogle Scholar
  • 131 Nicolls M R, Terada L S, Tuder R M, Priniville S A, Schwarz M I. Diffuse alveolar hemorrhage with underlying pulmonary capillaritis in the retinoic acid syndrome.  Am J Respir Crit Care Med. 1998;  158 1302-1305
    PubMedGoogle Scholar
  • 132 Camacho L H, Soignet S L, Chanel S et al.. Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide.  J Clin Oncol. 2000;  18 2620-2625
    PubMedGoogle Scholar
  • 133 Davis B A, Cervi P, Amin Z, Moshi G, Shaw P, Porter J. Retinoic acid syndrome: pulmonary computed tomography (CT) findings.  Leuk Lymphoma. 1996;  23 113-117
    PubMedGoogle Scholar
  • 134 Maloisel F, Petit T, Kessler R, Oberling F. Cytologic examination of broncho-alveolar fluid during the retinoic acid syndrome.  Eur J Haematol. 1996;  56 319-320
    PubMedGoogle Scholar
  • 135 Wiley J S, Firkin F C. Reduction of pulmonary toxicity by prednisolone prophylaxis during all-trans retinoic acid treatment of acute promyelocytic leukemia.  Leukemia. 1995;  9 774-778
    PubMedGoogle Scholar
  • 136 Goldschmidt N, Gural A, BenYehuda D. Extensive splenic infarction, deep vein thrombosis and pulmonary emboli complicating induction therapy with all-trans-retinoic acid (ATRA) for acute promyelocytic leukemia.  Leuk Lymphoma. 2003;  44 1433-1437
    CrossrefPubMedGoogle Scholar
  • 137 Weiss R B, Poster D S, Penta J S. The nitrosoureas and pulmonary toxicity.  Cancer Treat Rev. 1981;  8 111-125
    PubMedGoogle Scholar
  • 138 Smith A C. The pulmonary toxicity of nitrosoureas.  1989;  41 443-460
    PubMedGoogle Scholar
  • 139 Massin F, Coudert B, Foucher P et al.. Nitrosourea-induced pneumonitis.  Rev Mal Respir. 1992;  9 575-582
    PubMedGoogle Scholar
  • 140 Aronin P A, Mahaley M SJ, Rudnick S A et al.. Prediction of BCNU pulmonary toxicity in patients with malignant gliomas: an assessment of risk factors.  N Engl J Med. 1980;  303 183-188
    PubMedGoogle Scholar
  • 141 Tucci E, Verdiani P, Di Carlo S, Sforza V. Lomustine (CCNU)-induced pulmonary fibrosis.  Tumori. 1986;  72 95-98
    PubMedGoogle Scholar
  • 142 Mitsudo S M, Greenwald E S, Banerji B, Koss L G. BCNU (1 3-bis-(2-chloroethyl)-1-nitrosourea) lung: drug-induced pulmonary changes.  Cancer. 1984;  54 751-755
    PubMedGoogle Scholar
  • 143 Lohani S, O'Driscoll B R, Woodcock A A. 25-year study of lung fibrosis following carmustine therapy for brain tumor in childhood.  Chest. 2004;  126 1007
    CrossrefPubMedGoogle Scholar
  • 144 Ishizuka M, Takayama H, Takeuchi T, Umezawa H. Activity and toxicity of bleomycin.  J Antibiot (Tokyo). 1967;  20 15-24
    PubMedGoogle Scholar
  • 145 Balikian J P, Jochelson M S, Bauer K A et al.. Pulmonary complications of chemotherapy regimens containing bleomycin.  AJR Am J Roentgenol. 1982;  139 455-461
    PubMedGoogle Scholar
  • 146 Trump D L, Bartel E, Pozniak M. Nodular pneumonitis after chemotherapy for germ cell tumors.  Ann Intern Med. 1988;  109 431-432
    PubMedGoogle Scholar
  • 147 Iacovino J R, Leitner J, Abbas A K, Lokich J J, Snider G L. Fatal pulmonary reaction from low doses of bleomycin: an idiosyncratic tissue response.  JAMA. 1976;  235 1253-1255
    CrossrefPubMedGoogle Scholar
  • 148 Bechard D E, Fairman R P, DeBlois G G, Via C T. Fatal pulmonary fibrosis from low-dose bleomycin therapy.  South Med J. 1987;  80 646-649
    CrossrefPubMedGoogle Scholar
  • 149 Einhorn L, Krause M, Hornbarck N, Furnas B. Enhanced pulmonary toxicity with bleomycin and radiotherapy in oat cell lung cancer.  Cancer. 1976;  37 2414-2416
    PubMedGoogle Scholar
  • 150 Krous H F, Hamlin W B. Pulmonary toxicity due to bleomycin: report of a case.  Arch Pathol. 1973;  95 407-410
    PubMedGoogle Scholar
  • 151 Toledo C H, Ross W E, Hood C I, Block E R. Potentiation of bleomycin toxicity by oxygen.  Cancer Treat Rep. 1982;  66 359-362
    PubMedGoogle Scholar
  • 152 White D A, Stover D E. Severe bleomycin-induced pneumonitis: clinical features and response to corticosteroids.  Chest. 1984;  86 723-728
    PubMedGoogle Scholar
  • 153 Simpson A B, Paul J, Graham J, Kaye S B. Fatal bleomycin pulmonary toxicity in the west of Scotland 1991-95: a review of patients with germ cell tumours.  Br J Cancer. 1998;  78 1061-1066
    PubMedGoogle Scholar
  • 154 Kawai K, Akaza H. Bleomycin-induced pulmonary toxicity in chemotherapy for testicular cancer.  Expert Opin Drug Saf. 2003;  2 587-596
    CrossrefPubMedGoogle Scholar
  • 155 Bargon G. Drug-induced changes in the lungs.  Rontgenblatter. 1984;  37 261-265
    PubMedGoogle Scholar
  • 156 Bellamy E A, Husband J E, Blaquiere R M, Law M R. Bleomycin related lung damage: CT evidence.  Radiology. 1985;  156 155-158
    PubMedGoogle Scholar
  • 157 Kuhlman J E. The role of chest computed tomography in the diagnosis of drug-related reactions.  J Thorac Imaging. 1991;  6 52-61
    PubMedGoogle Scholar
  • 158 Daba M H, El-Tahir K E, Al-Arifi M N, Gubara O A. Drug-induced pulmonary fibrosis.  Saudi Med J. 2004;  25 700-706
    PubMedGoogle Scholar
  • 159 Bellamy E A, Nicholas D, Husband J E. Quantitative assessment of lung damage due to bleomycin using computed tomography.  Br J Radiol. 1987;  60 1205-1209
    PubMedGoogle Scholar
  • 160 Mills P, Husband J. Computed tomography of pulmonary bleomycin toxicity.  Semin Ultrasound CT MR. 1990;  11 417-422
    PubMedGoogle Scholar
  • 161 Rimmer M J, Dixon A K, Flower C DR, Sikora K. Bleomycin lung: computed tomographic observations.  Br J Radiol. 1985;  58 1041-1045
    PubMedGoogle Scholar
  • 162 White D A, Kris M G, Stover D E. Bronchoalveolar lavage cell populations in bleomycin lung toxicity.  Thorax. 1987;  42 551-552
    PubMedGoogle Scholar
  • 163 Yousem S A, Lifson J D, Colby T V. Chemotherapy-induced eosinophilic pneumonia: relation to bleomycin.  Chest. 1985;  88 103-106
    PubMedGoogle Scholar
  • 164 O'Neill T J, Kardinal C G, Tierney L M. Reversible interstitial pneumonitis associated with low-dose bleomycin.  Chest. 1975;  68 265-267
    PubMedGoogle Scholar
  • 165 Lewis B M, Izbicki R. Routine pulmonary function tests during bleomycin therapy. Tests may be ineffective and potentially misleading.  JAMA. 1980;  243 347-351
    CrossrefPubMedGoogle Scholar
  • 166 Schaaf W, Vogel H, Kresuer E, Demandt M. Postoperative ARDS as a possible consequence of bleomycin therapy performed 7 years ago: a case study.  Anästhesiol Intensivmed. 2003;  44 436-440
    PubMedGoogle Scholar
  • 167 Kopko P M, Popovsky M A. Pulmonary injury from transfusion-related acute lung injury.  Clin Chest Med. 2004;  25 105-113
    CrossrefPubMedGoogle Scholar
  • 168 Kopko P M, Marshall C S, MacKenzie M R, Holland P V, Popovsky M A. Transfusion-related acute lung injury. Report of a clinical look-back investigation.  JAMA. 2002;  287 1968-1971
    CrossrefPubMedGoogle Scholar
  • 169 Popovsky M A. Transfusion and lung injury.  Transfus Clin Biol. 2001;  8 272-277
    CrossrefPubMedGoogle Scholar
  • 170 Gajic O, Moore S B. Transfusion-related acute lung injury.  Mayo Clin Proc. 2005;  80 766-770
    CrossrefPubMedGoogle Scholar
  • 171 Carilli A D, Ramamurthy M V, Chang Y-S, Shin D, Sehti V. Noncardiogenic pulmonary edema following blood transfusion.  Chest. 1978;  74 310-312
    PubMedGoogle Scholar
  • 172 Popovsky M A. Transfusion and the lung: circulatory overload and acute lung injury.  Vox Sang. 2004;  87 62-65
    CrossrefPubMedGoogle Scholar
  • 173 Dubois M, Lotze M T, Diamond W J, Kim Y D, Flye M W, MacNamara T E. Pulmonary shunting during leukoagglutinin-induced noncardiac pulmonary edema.  JAMA. 1980;  244 2186-2189
    CrossrefPubMedGoogle Scholar
  • 174 Yost C S, Matthay M A, Gropper M A. Etiology of acute pulmonary edema during liver transplantation.  Chest. 2001;  119 219-223
    CrossrefPubMedGoogle Scholar
  • 175 Levy G J, Shabot M M, Hart M E, Mya W W, Goldfinger D. Tranfusion-associated noncardiogenic pulmonary edema: report of a case and a warning regarding treatment.  Transfusion. 1986;  26 278-281
    CrossrefPubMedGoogle Scholar
  • 176 Massin F, Fur A, Reybet-Degat O, Camus P, Jeannin L. Busulfan-induced pneumonitis.  Rev Mal Respir. 1987;  4 3-10
    PubMedGoogle Scholar
  • 177 Nelson B M, Andrews G A. Breast cancer and cytologic dysplasia in many organs after Busulfan.  Am J Clin Pathol. 1964;  42 37-44
    PubMedGoogle Scholar
  • 178 [No authors listed.] . Case records of the Massachusetts General Hospital: case 25-1997.  N Engl J Med. 1997;  337 480-489
    CrossrefPubMedGoogle Scholar
  • 179 Kirschner R H, Esterly J R. Pulmonary lesions associated with busulfan therapy of chronic myelogenous leukemia.  Cancer. 1971;  27 1074-1080
    PubMedGoogle Scholar
  • 180 Aymard J P, Gyger M, Lavallee R, Legresley L P, Desy M. A case of pulmonary alveolar proteinosis complicating chronic myelogenous leukemia: a peculiar pathologic aspect of busulfan lung?.  Cancer. 1984;  53 954-956
    PubMedGoogle Scholar
  • 181 Littler W A, Ogilvie C. Lung function in patients receiving busulphan.  Br Med J. 1970;  ii 530-532
    PubMedGoogle Scholar
  • 182 Giles F J, Smith M P, Goldstone A H. Chlorambucil lung toxicity.  Acta Haematol. 1990;  83 156-158
    PubMedGoogle Scholar
  • 183 Mohr M, Kingreen D, Rühl H, Huhn D. Interstitial lung disease: an underdiagnosed side-effect of chlorambucil?.  Ann Hematol. 1993;  67 305-307
    CrossrefPubMedGoogle Scholar
  • 184 Khong H T, McCarthy J. Chlorambucil-induced pulmonary disease: a case report and review of the literature.  Ann Hematol. 1998;  77 85-87
    CrossrefPubMedGoogle Scholar
  • 185 Ruiz-Argüelles G J, Arizpe-Bravo D, Sanchez-Sosa S, Rojas-Ortega S, Moreno-Ford V, Ruiz-Argüelles A. Fatal G-CSF-induced pulmonary toxicity.  Am J Hematol. 1999;  60 82-83
    CrossrefPubMedGoogle Scholar
  • 186 Lei K IK, Leung W T, Johnson P J. Serious pulmonary complications in patients receiving recombinant granulocyte colony-stimulating factor during BACOP chemotherapy for agressive non-Hodgkin's lymphoma.  Br J Cancer. 1994;  70 1009-1013
    PubMedGoogle Scholar
  • 187 Yokose N, Ogata K, Tamura H et al.. Pulmonary toxicity after granulocyte colony stimulating factor-combined chemotherapy for non-Hodgkin's lymphoma.  Br J Cancer. 1998;  77 2286-2290
    PubMedGoogle Scholar
  • 188 Saxman S B, Nichols C R, Einhorn L H. Pulmonary toxicity in patients with advanced-stage germ cell tumors receiving bleomycin with and without granulocyte colony stimulating factor.  Chest. 1997;  111 657-660
    PubMedGoogle Scholar
  • 189 Gatti E, Scagliotti G V, Ferrari G et al.. Blood cell redistribution in the lung after administration of recombinant human granulocyte-macrophage colony-stimulating factor.  Eur Respir J. 1995;  8 1566-1571
    PubMedGoogle Scholar
  • 190 Philippe B, Couderc L J, Balloul-Delclaux E, Janvier M, Caubarrère I. Pulmonary toxicity of chemotherapy and GM-CSF.  Respir Med. 1994;  88 715
    PubMedGoogle Scholar
  • 191 Sorhage F, Stover D E, Mortazavi A. Unusual etiology of cough in a woman with asthma.  Chest. 1996;  110 852-854
    PubMedGoogle Scholar
  • 192 Taillé C, Fartoukh M, Houël R, Kobeiter H, Rémy P, Lemaire F. Spontaneous hemomediastinum complicating steroid-induced mediastinal lipomatosis.  Chest. 2001;  120 311-313
    CrossrefPubMedGoogle Scholar
  • 193 Decramer M, de Bock V, Dom R. Functional and histologic picture of steroid-induced myopathy in chronic obstructive pulmonary disease.  Am J Respir Crit Care Med. 1996;  153 1958-1964
    PubMedGoogle Scholar
  • 194 Similowski T, Strauss C. Iatrogenic-induced dysfunction of the neuromuscular respiratory system.  Clin Chest Med. 2004;  25 155-166
    CrossrefPubMedGoogle Scholar
  • 195 Kilpiö K, Hannuksela M. Corticosteroid allergy in asthma.  Allergy. 2003;  58 1131-1135
    CrossrefPubMedGoogle Scholar
  • 196 Lionakis M S, Kontoyiannis D P. Glucocorticoids and invasive fungal infections.  Lancet. 2003;  362 1828-1838
    CrossrefPubMedGoogle Scholar
  • 197 Wolley J, Collett J, Goldstein D. Diffuse alveolar damage following a single administration of a cyclophosphamide containing chemotherapy regimen.  Aust NZ J Med. 1997;  27 605-606
    PubMedGoogle Scholar
  • 198 Cuguillière A, Bérard H, N'Guyen G. Pneumopathie interstitielle liée au cyclophosphamide.  Rev Pneumol Clin. 1999;  55 100-104
    PubMedGoogle Scholar
  • 199 Burke D A, Stoddart J C, Ward M K, Simpson C GB. Fatal pulmonary fibrosis occurring during treatment with cyclophosphamide.  Br Med J. 1982;  285 696
    PubMedGoogle Scholar
  • 200 Abdel Karim F W, Ayash R E, Allam C, Salem P A. Pulmonary fibrosis after prolonged treatment with low-dose cyclophosphamide.  Oncology. 1983;  40 174-176
    PubMedGoogle Scholar
  • 201 Topilow A A, Rothenberg S P, Cottrell T S. Interstitial pneumonia after prolonged treatment with cyclophosphamide.  Am Rev Respir Dis. 1973;  108 114-117
    PubMedGoogle Scholar
  • 202 Alvarado C S, Boat T F, Newman A J. Late-onset pulmonary fibrosis and chest deformity in two children treated with cyclophosphamide.  J Pediatr. 1978;  92 443-446
    PubMedGoogle Scholar
  • 203 Kulke M H, Vance E A. Pneumocystis carinii pneumonia in patients receiving chemotherapy for breast cancer.  Clin Infect Dis. 1997;  25 215-218
    PubMedGoogle Scholar
  • 204 [No authors listed.] . Case records of the Massachusetts General Hospital: case 35-1984.  N Engl J Med. 1984;  311 585-593
    PubMedGoogle Scholar
  • 205 Haupt H M, Hutchins G M, Moore G W. Ara-C lung: non-cardiogenic pulmonary edema complicating cytosine arabinoside therapy of leukaemia.  Am J Med. 1981;  70 256-261
    CrossrefPubMedGoogle Scholar
  • 206 Jehn U, Göldel N, Rienmüller R, Wilmanns W. Non-cardiogenic pulmonary edema complicating intermediate and high-dose Ara C treatment for relapsed acute leukemia.  Med Oncol Tumor Pharmacother. 1988;  5 41-47
    PubMedGoogle Scholar
  • 207 Shearer P, Katz J, Bozeman P et al.. Pulmonary insufficiency complicating therapy with high dose cytosine arabinoside in five pediatric patients with relapsed acute myelogenous leukemia.  Cancer. 1994;  74 1953-1958
    CrossrefPubMedGoogle Scholar
  • 208 Andersson B S, Luna B S, Yee C, Hui K K, Keating M J, McCreadie K B. Fatal pulmonary failure complicating high-dose cytosine arabinoside therapy in acute leukemia.  Cancer. 1990;  65 1079-1084
    CrossrefPubMedGoogle Scholar
  • 209 Tenenbein M, Adamson I YR. Desferrioxamine and pulmonary injury.  Lancet. 1992;  340 428-429
    PubMedGoogle Scholar
  • 210 Freedman M H, Grisaru D, Olivieri N, McLusky I, Thorner P S. Pulmonary syndrome in patients with thalassemia major receiving intravenous deferoxamine infusions.  Am J Dis Child. 1990;  144 565-569
    PubMedGoogle Scholar
  • 211 Miller K B, Rosenwasser L J, Bessette J AM, Beer D J, Rocklin R E. Rapid desensitization for desferrioxamine anaphylactic reaction.  Lancet. 1981;  1 1059
    PubMedGoogle Scholar
  • 212 Fassas A, Gojo I, Rapoport A et al.. Pulmonary toxicity syndrome following CDEP (cyclophosphamide, dexamethasone, etoposide, cisplatin) chemotherapy.  Bone Marrow Transplant. 2001;  28 399-403
    CrossrefPubMedGoogle Scholar
  • 213 Solal-Celigny P, Brice P, Brousse N et al.. Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: a multicenter study by the Groupe d'Etude des Lymphomes de l'Adulte.  J Clin Oncol. 1996;  14 514-519
    PubMedGoogle Scholar
  • 214 Cervantes F, Salgado C, Montserrat E, Rozman C. Fludarabine for prolymphocytic leukaemia and risk of interstitial pneumonitis.  Lancet. 1990;  336 1130
    PubMedGoogle Scholar
  • 215 Helman D LJ, Byrd J C, Ales N C, Shorr A F. Fludarabine-related pulmonary toxicity: a distinct clinical entity in chronic lymphoproliferative syndromes.  Chest. 2002;  122 785-790
    CrossrefPubMedGoogle Scholar
  • 216 Trojan A, Meier R, Licht A, Taverna C. Eosinophilic pneumonia after administration of fludarabine for the treatment of non-Hodgkin's lymphoma.  Ann Hematol. 2002;  81 535-537
    CrossrefPubMedGoogle Scholar
  • 217 Ales N C, Helman D L, Shorr A F, Byrd J C. Fludarabine associated pulmonary toxicity in chronic in lymphoproliferative disoders: a case series.  Blood. 2000;  96 756a-757a
    PubMedGoogle Scholar
  • 218 Pavlakis N, Bell D R, Millward M J, Levi J A. Fatal pulmonary toxicity resulting from treatment with gemcitabine.  Cancer. 1997;  80 286-291
    CrossrefPubMedGoogle Scholar
  • 219 Barlési F, Villani P, Doddoli C, Gimenez C, Kleisbauer J P. Gemcitabine-induced severe pulmonary toxicity.  Fundam Clin Pharmacol. 2004;  18 85-91
    CrossrefPubMedGoogle Scholar
  • 220 Maniwa K, Tanaka E, Inoue T et al.. An autopsy case of acute pulmonary toxicity associated with gemcitabine.  Intern Med. 2003;  42 1022-1025
    PubMedGoogle Scholar
  • 221 Marruchella A, Fiorenzano G, Merizzi A, Rossi G, Chiodera P L. Diffuse alveolar damage in a patient treated with gemcitabine.  Eur Respir J. 1998;  11 504-506
    CrossrefPubMedGoogle Scholar
  • 222 Sauer-Heilborn A, Kath R, Schneider C P, Hoeffken K. Severe non-haematological toxicity after treatment with gemcitabine.  J Cancer Res Clin Oncol. 1999;  125 637-640
    CrossrefPubMedGoogle Scholar
  • 223 Desramé J, Duvic C, Bredin C et al.. Hemolytic uremic syndrome as a complication of gemcitabine treatment: report of six cases and review of the literature.  Rev Med Interne. 2005;  26 179-188
    PubMedGoogle Scholar
  • 224 Schwonzen M, Spangenberger H, Spengler M. Hydroxyurea-induced pneumonitis.  Med Klin (Munich). 2003;  98 394-397
    CrossrefPubMedGoogle Scholar
  • 225 Antoniou K M, Ferdoutsis E, Bouros D. Interferons and their application in the diseases of the lung.  Chest. 2003;  123 209-216
    CrossrefPubMedGoogle Scholar
  • 226 Ramos-Casals M, Mana J, Nardi N et al.. Sarcoidosis in patients with chronic hepatitis C virus infection: analysis of 68 cases.  Medicine (Baltimore). 2005;  84 69-80
    CrossrefPubMedGoogle Scholar
  • 227 Ishizaki T, Sasaki F, Ameshima S et al.. Pneumonitis during interferon and/or herbal drug therapy in patients with chronic active hepatitis.  Eur Respir J. 1996;  9 2691-2696
    PubMedGoogle Scholar
  • 228 Moriya K, Yasuda K, Koike K et al.. Induction of interstitial pneumonitis during interferon treatment for chronic hepatitis C.  J Gastroenterol. 1994;  29 514-517
    PubMedGoogle Scholar
  • 229 Anderson P, Höglund M, Rödjer S. Pulmonary side effects of interferon-α therapy in patients with hematological malignancies.  Am J Hematol. 2003;  73 54-58
    CrossrefPubMedGoogle Scholar
  • 230 Kamisako T, Adachi Y, Chihara J, Yamamoto T. Interstitial pneumonitis and interferon-alfa.  BMJ. 1993;  306 896
    PubMedGoogle Scholar
  • 231 Hoffman S D, Hammadeh R, Shah N. Eosinophilic pneumonitis secondary to pegylated interferon alpha-2b and/or ribavirin.  Am J Gastroenterol. 2003;  98 S152
    PubMedGoogle Scholar
  • 232 Ogata K, Koga T, Yagawa K. Interferon-related bronchiolitis obliterans organizing pneumonia.  Chest. 1994;  106 612-613
    PubMedGoogle Scholar
  • 233 Kumar K S, Russo M W, Borczuk A C. Significant pulmonary toxicity associated with interferon and ribavirin therapy for hepatitis C.  Am J Gastroenterol. 2002;  97 2432-2440
    CrossrefPubMedGoogle Scholar
  • 234 Kumar K S, Russo M W, Borczuk A C et al.. Significant pulmonary toxicity associated with interferon and ribavirin therapy for hepatitis C.  Am J Gastroenterol. 2002;  97 2432-2440
    CrossrefPubMedGoogle Scholar
  • 235 Pileire G, Leclerc P, Hermant P, Meeus E, Camus P. Toux chronique isolée pendant un traitement par interféron.  Presse Med. 1999;  28 913
    PubMedGoogle Scholar
  • 236 Krasnowska M, Malolepszy J, Liebhart E. Interferon as a bronchospastic factor in patients with bronchial asthma.  Pneumonol Alergol Pol. 1992;  60 22-25
    PubMedGoogle Scholar
  • 237 Takeda A, Ikegame K, Kimura Y, Ogawa H, Kanazawa S, Nakamura H. Pleural effusion during interferon treatment for chronic hepatitis C.  Hepatogastroenterology. 2000;  47 1431-1435
    PubMedGoogle Scholar
  • 238 Fruehauf S, Steiger S, Topaly J, Ho A D. Pulmonary artery hypertension during interferon-alpha therapy for chronic myelogenous leukemia.  Ann Hematol. 2001;  80 308-310
    CrossrefPubMedGoogle Scholar
  • 239 Price E J, Venables P J. Drug-induced lupus.  Drug Saf. 1995;  12 283-290
    PubMedGoogle Scholar
  • 240 Shaw E G, Deming R L, Creagan E T et al.. Pilot study of human recombinant interferon gamma and accelerated hyperfractionated thoracic radiation therapy in patients with unresectable stage IIIA/B nonsmall cell lung cancer.  Int J Radiat Oncol Biol Phys. 1995;  31 827-831
    CrossrefPubMedGoogle Scholar
  • 241 Honoré I, Nunes H, Groussard O et al.. Acute respiratory failure after interferon-gamma therapy of end-stage pulmonary fibrosis.  Am J Respir Crit Care Med. 2003;  167 953-957
    CrossrefPubMedGoogle Scholar
  • 242 Bergeron A, Bergot E, Vilela G et al.. Hypersensitivity pneumonitis related to imatinib mesylate.  J Clin Oncol. 2002;  20 4271-4272
    CrossrefPubMedGoogle Scholar
  • 243 Yokoyama T, Miyazawa K, Kurakawa E et al.. Interstitial pneumonia induced by imatinib mesylate: pathologic study demonstrates alveolar destruction and fibrosis with eosinophilic infiltration.  Leukemia. 2004;  18 645-646
    CrossrefPubMedGoogle Scholar
  • 244 Ma C X, Hobday T J, Jett J R. Imatinib mesylate-induced interstitial pneumonitis.  Mayo Clin Proc. 2003;  78 1578-1579
    PubMedGoogle Scholar
  • 245 Wagner U, Staats P, Moll R, Feek U, Vogelmeier C, Groneberg D A. Imatinib-associated pulmonary alveolar proteinosis.  Am J Med. 2003;  115 674
    PubMedGoogle Scholar
  • 246 Taetle R, Dickman P S, Feldman P S. Pulmonary histopathologic changes associated with melphalan therapy.  Cancer. 1978;  42 1239-1245
    PubMedGoogle Scholar
  • 247 Mufti G J, Hamblin T J, Gordon J. Melphalan-induced pulmonary fibrosis in osteosclerotic myeloma.  Acta Haematol. 1983;  69 140-141
    PubMedGoogle Scholar
  • 248 Lioté H, Gauthier J F, Prier A, Gauthier-Rahman S, Kaplan G, Akoun G. Acute, reversible, interstitial pneumopathy induced by melphalan.  Rev Mal Respir. 1989;  6 461-464
    PubMedGoogle Scholar
  • 249 Akasheh M S, Freytes C O, Vesole D H. Melphalan-associated pulmonary toxicity following high-dose therapy with autologous hematopoietic stem cell transplantation.  Bone Marrow Transplant. 2000;  26 1107-1109
    CrossrefPubMedGoogle Scholar
  • 250 Major P P, Laurin S, Bettez P. Pulmonary fibrosis following therapy with melphalan: report of two cases.  Can Med Assoc J. 1980;  123 197-202
    PubMedGoogle Scholar
  • 251 Clarysse A M, Cathey W J, Cartwright G E, Wintrobe M M. Pulmonary disease complicating intermittent therapy with methotrexate.  JAMA. 1969;  209 1861-1864
    CrossrefPubMedGoogle Scholar
  • 252 Massin F, Coudert B, Marot J P, Foucher P, Camus P, Jeannin L. Methotrexate pneumonitis.  Rev Mal Respir. 1990;  7 5-15
    PubMedGoogle Scholar
  • 253 Kremer J M, Joong K L. The safety and efficacy of the use of methotrexate in long term therapy for rheumatoid arthritis.  Arthritis Rheum. 1986;  29 822-831
    CrossrefPubMedGoogle Scholar
  • 254 van der Veen M J, Dekker J J, Dinant H J, Van Soesbergen R M, Bijlsma J WJ. Fatal pulmonary fibrosis complicating low dose methotrexate therapy for rheumatoid arthritis.  J Rheumatol. 1995;  22 1766-1768
    PubMedGoogle Scholar
  • 255 Renaudier P, Chabot F, Ferry R et al.. Pneumopathies du méthotrexate survenant dans le cadre du traitement des lymphomes non hodkiniens par le protocole m-BACOD.  Bull Cancer. 1995;  82 149-154
    PubMedGoogle Scholar
  • 256 Pourel J, Guillemin F, Fener P, Webanck L, Bene M-C, Delorme N. Delayed methotrexate pneumonitis in rheumatoid arthritis.  J Rheumatol. 1991;  18 303-304
    PubMedGoogle Scholar
  • 257 Everts C S, Wescott J L, Bragg D G. Methotrexate therapy and pulmonary disease.  Radiology. 1973;  107 539-543
    PubMedGoogle Scholar
  • 258 Akoun G M, Mayaud C M, Touboul J L, Denis M F, Milleron B J, Perrot B J. Use of bronchoalveolar lavage in the evaluation of methotrexate lung disease.  Thorax. 1987;  42 652-655
    PubMedGoogle Scholar
  • 259 White D A, Rankin J A, Stover D E, Gellene R A, Gupta S. Methotrexate pneumonitis: bronchoalveolar lavage findings suggest an immunologic disorder.  Am Rev Respir Dis. 1989;  139 18-21
    CrossrefPubMedGoogle Scholar
  • 260 Imokawa S, Sato A, Hayakawa H, Toyoshima M, Taniguchi M, Chida K. Possible involvement of an environmental agent in the development of acute eosinophilic pneumonia.  Ann Allergy Asthma Immunol. 1996;  76 419-422
    PubMedGoogle Scholar
  • 261 Logan P M, Primack S L, Staples C, Miller R R, Müller N L. Acute lung disease in the immunocompromised host: diagnostic accuracy of the chest radiograph.  Chest. 1995;  108 1283-1287
    PubMedGoogle Scholar
  • 262 Kane G C, Troshinsky M B, Peters S P, Israel H L. Pneumocystis carinii pneumonia associated with weekly methotrexate: cumulative dose of methotrexate and low CD4 cell count may predict this complication.  Respir Med. 1993;  87 153-155
    PubMedGoogle Scholar
  • 263 Dai M S, Ho C L, Chen Y C, Kao W Y, Chao T Y. Acute respiratory distress syndrome following intrathecal methotrexate administration: a case report and review of literature.  Ann Hematol. 2000;  79 696-699
    CrossrefPubMedGoogle Scholar
  • 264 Schnabel A, Dalhoff K, Bauerfeind S, Barth J, Gross W L. Sustained cough in methotrexate therapy for rheumatoid arthritis.  Clin Rheumatol. 1996;  15 277-282
    CrossrefPubMedGoogle Scholar
  • 265 Newman E D, Harrington T M. Fatal methotrexate pneumonitis in rheumatoid arthritis.  Arthritis Rheum. 1988;  31 1585-1586
    PubMedGoogle Scholar
  • 266 Cottin V, Tébib J, Massonnet B, Souquet P J, Bernard J-P. Pulmonary function in patients receiving long-term low-dose methotrexate.  Chest. 1996;  109 933-938
    CrossrefPubMedGoogle Scholar
  • 267 Mahmood T, Mudad R. Pulmonary toxicity secondary to procarbazine.  Am J Clin Oncol. 2002;  25 187-188
    CrossrefPubMedGoogle Scholar
  • 268 Duggan D B, Petroni G R, Johnson J L et al.. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial.  J Clin Oncol. 2003;  21 607-614
    CrossrefPubMedGoogle Scholar
  • 269 Jones S E, Moore M, Blank N, Castellino R A. Hypersensitivity to procarbazine (Matulane) manifested by fever and pleuropulmonary reaction.  Cancer. 1972;  29 498-500
    CrossrefPubMedGoogle Scholar
  • 270 Ecker M D, Jay B, Keohane M F. Procarbazine lung.  AJR Am J Roentgenol. 1978;  131 527-528
    PubMedGoogle Scholar
  • 271 Horton L WL, Chappell A G, Powell D EB. Diffuse interstitial pulmonary fibrosis complicating Hodgkin's disease.  Br J Dis Chest. 1977;  71 44-48
    PubMedGoogle Scholar
  • 272 Rosenow E C. Chemotherapeutic drug-induced pulmonary disease.  Respir Med. 1980;  2 89-96
    PubMedGoogle Scholar
  • 273 Cook R C, Connors J M, Gascoyne R D, Fradet G, Levy R D. Treatment of post-transplant lymphoproliferative disease with rituximab monoclonal antibody after lung transplantation.  Lancet. 1999;  354 1698-1699
    CrossrefPubMedGoogle Scholar
  • 274 Zerga M, Cerchetti L, Cicco J, Constantini P, De Riz M. Desquamative alveolitis: an unusual complication of treatment with Mabthera.  Blood. 1999;  94 271
    PubMedGoogle Scholar
  • 275 Mangel J, Buckstein R, Imrie K et al.. Pulmonary complications after autologous transplantation and immunotherapy with rituximab in patients with follicular lymphoma [abstract].  Blood. 2000;  96 383a
    PubMedGoogle Scholar
  • 276 Burton C, Kaczmarski R, Jan-Mohamed R. Interstitial pneumonitis related to rituximab therapy.  N Engl J Med. 2003;  348 2690-2691
    CrossrefPubMedGoogle Scholar
  • 277 Alexandrescu D T, Dutcher J P, O'Boyle K, Albulak M, Oiseth S, Wiernik P H. Fatal intra-alveolar hemorrhage after rituximab in a patient with non-Hodgkin lymphoma.  Leukemia Lymphoma. 2004;  45 2321-2325
    PubMedGoogle Scholar
  • 278 Leon R J, Gonsalvo A, Salas R, Hidalgo N C. Rituximab-induced acute pulmonary fibrosis.  Mayo Clin Proc. 2004;  79 949-953
    CrossrefPubMedGoogle Scholar
  • 279 Swords R, Power D, Fay M, O'Donnell R, Murphy P T. Interstitial pneumonitis following rituximab therapy for immune thrombocytopenic purpura (ITP).  Am J Hematol. 2004;  77 103-104
    PubMedGoogle Scholar
  • 280 Hiraga J, Kondoh Y, Taniguchi H, Kinoshita T, Naoe T. A case of interstitial pneumonia induced by rituximab therapy.  Int J Hematol. 2005;  81 169-170
    PubMedGoogle Scholar
  • 281 Speirs A L. Thalidomide and congenital abnormalities.  Lancet. 1962;  1 303-305
    PubMedGoogle Scholar
  • 282 Carrion Valero F C. Lung toxicity due to thalidomide.  Arch Bronconeumol. 2003;  39 286
    CrossrefPubMedGoogle Scholar
  • 283 Diaz Garcia B, de Pablo Gafas A, Ferreiro Alvarez M J. Lung toxicity due to thalidomide.  Arch Bronconeumol. 2003;  39 240
    CrossrefPubMedGoogle Scholar
  • 284 Onozawa M, Hashino S, Sogabe S et al.. Thalidomide-induced interstitial pneumonitis.  J Clin Oncol. 2005;  23 2425-2426
    CrossrefPubMedGoogle Scholar
  • 285 Iguchi T, Sakoda M, Chen C K et al.. Interstitial pneumonia during treatment with thalidomide in a patient with multiple myeloma.  Rinsho Ketsueki. 2004;  45 1064-1066
    PubMedGoogle Scholar
  • 286 Younis T H, Alam A, Paplham P, Spangenthal E, McCarthy P. Reversible pulmonary hypertension and thalidomide therapy for multiple myeloma.  Br J Haematol. 2003;  121 191-192
    CrossrefPubMedGoogle Scholar
  • 287 Bennett C L, Schumock G T, Desai A A et al.. Thalidomide-associated deep vein thrombosis and pulmonary embolism.  Am J Med. 2002;  113 603-606
    CrossrefPubMedGoogle Scholar
  • 288 Steurer M, Sudmeier I, Stauder R, Gastl G. Thromboembolic events in patients with myelodysplastic syndrome receiving thalidomide in combination with darbepoietin-alpha.  Br J Haematol. 2003;  121 101-103
    CrossrefPubMedGoogle Scholar
  • 289 Warren S, Spencer J. Radiation reactions in the lung.  AJR Am J Roentgenol. 1940;  43 682-701
    PubMedGoogle Scholar
  • 290 Libshitz H I, Southard M E. Complications of radiation therapy: The thorax.  Semin Roentgenol. 1974;  9 41-49
    PubMedGoogle Scholar
  • 291 Gross N J. Pulmonary effects of radiation therapy.  Ann Intern Med. 1977;  86 81-92
    PubMedGoogle Scholar
  • 292 Pagani J J, Libshitz H I. CT manifestations of radiation-induced change in chest tissue.  J Comput Assist Tomogr. 1982;  6 243-248
    PubMedGoogle Scholar
  • 293 Davis S D, Yankelevitz D F, Henschke C I. Radiation effects on the lung: clinical features, pathology, and imaging findings.  AJR Am J Roentgenol. 1992;  159 1157-1164
    CrossrefPubMedGoogle Scholar
  • 294 Movsas B, Raffin T A, Epstein A H, Link C J. Pulmonary radiation injury.  Chest. 1997;  111 1061-1076
    PubMedGoogle Scholar
  • 295 Logan P M. Thoracic manifestations of external beam radiotherapy.  AJR Am J Roentgenol. 1998;  171 569-577
    PubMedGoogle Scholar
  • 296 Gibson P G, Bryant D H, Morgan G W et al.. Radiation-induced pneumonitis: a hypersensitivity pneumonitis?.  Ann Intern Med. 1988;  109 288-291
    PubMedGoogle Scholar
  • 297 Jochelson M S, Tarbell N J, Weinstein H J. Unusual thoracic radiographic findings in children treated for Hodgkin's disease.  J Clin Oncol. 1986;  4 874-882
    PubMedGoogle Scholar
  • 298 Goldman A L, Enquist R. Hyperacute radiation pneumonitis.  Chest. 1975;  67 613-615
    PubMedGoogle Scholar
  • 299 Loyer E, Fuller L, Libshitz H I, Palmer J L. Radiographic appearance of the chest following therapy for Hodgkin disease.  Eur J Radiol. 2000;  35 136-148
    CrossrefPubMedGoogle Scholar
  • 300 Crestanello J A, McGregor C GA, Danielson G K et al.. Mitral and tricuspid valve repair in patients with previous mediastinal radiation therapy.  Ann Thorac Surg. 2004;  78 826-831
    CrossrefPubMedGoogle Scholar

Philippe CamusM.D. 

Department of Pulmonary Medicine and Intensive Care, Hopital Le Bocage BP 1542, 21034 Dijon, France

Email: philippe.camus@chu-dijon.fr

URL: http://www.pneumotox.com